• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Net clinical benefit of direct oral anticoagulants in atrial fibrillation patients with or without diabetes mellitus: a meta-analysis of outcome trials
Direct oral anticoagulants (DOACs) are gradually replacing warfarin in the treatment of non-valvular atrial fibrillation because outcome comparison trials were constantly associated with a reduction of 1) stroke or systemic embolism events, and 2) major bleeding events [1 –4]. Whether the beneficial effect of DOACs vs warfarin on fatal and non-fatal outcomes is consistent to patients with or without diabetes mellitus (DM) has been previously approached by meta-analyses of the available outcome trials [5–7], in which no differential outcome effect was noticed.
Source: Diabetes Research and Clinical Practice - November 15, 2021 Category: Endocrinology Authors: Sotirios Drogkaris, Costas Thomopoulos, Theodoros Kalos, Eleni Manta, Costas Tsioufis Source Type: research

Direct Oral Anticoagulants in Atrial Fibrillation Patients with Concomitant Hyperthyroidism.
CONCLUSION: Among NVAF Asian patients with concomitant hyperthyroidism, DOACs may be an effective and safer alternative to warfarin. Thromboprophylaxis with DOACs may be considered for such patients, and it is important to validate this finding in further prospective study. PMID: 32009154 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - February 2, 2020 Category: Endocrinology Authors: Chan YH, Wu LS, See LC, Liu JR, Chang SH, Chao TF, Yeh YH, Kuo CT, Lee HF, Lip GYH Tags: J Clin Endocrinol Metab Source Type: research

The continuous challenge of antithrombotic strategies in diabetes: focus on direct oral anticoagulants
AbstractDirect oral anticoagulants (DOACs) include dabigatran, which inhibits thrombin, and apixaban, edoxaban, and rivaroxaban, which inhibit factor Xa. They have been extensively studied in large trials involving patients affected by the most common cardiovascular diseases. As the presence of diabetes leads to peculiar changes in primary and secondary hemostasis, in this review we highlight the current evidence regarding DOAC use in diabetic patients included in the majority of recently conducted studies. Overall, in trials involving patients with atrial fibrillation, data seem to confirm at least a similar efficacy and ...
Source: Acta Diabetologica - September 23, 2019 Category: Endocrinology Source Type: research

Use of non ‐vitamin K oral anticoagulants in people with atrial fibrillation and diabetes mellitus
ConclusionsThe efficacy and safety of non‐vitamin K oral anticoagulants compared with warfarin generally extend to participants with diabetes mellitus, although dedicated randomized trials or real‐world data are lacking.This article is protected by copyright. All rights reserved.
Source: Diabetic Medicine - February 13, 2018 Category: Endocrinology Authors: O. Itzhaki, B. Zadok, A. Eisen Tags: Review Source Type: research

Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: A study ‐level meta‐analysis of phase III randomized trials
In this study‐level meta‐analysis, we included 4 randomized phase III trials comparing NOACs and warfarin in patients with nonvalvular AF; a total of 18 134 patients with DM and 40 454 without DM were overall considered. Incidence of the following outcome measures was evaluated during the follow‐up: stroke or systemic embolism, ischemic stroke, major bleeding, intracranial bleeding, and vascular death. Use of NOACs compared with warfarin reduced stroke/systemic embolism in diabetic (Risk Ratios [RR] 0.80, 95% CI 0.68‐0.93; P = .004) and nondiabetic patients (RR 0.83, 0.73‐0.93; P = .001) (P for interaction ...
Source: Diabetes/Metabolism Research and Reviews - January 26, 2017 Category: Endocrinology Authors: Giuseppe Patti, Giuseppe Di Gioia, Ilaria Cavallari, Antonio Nenna Tags: REVIEW ARTICLE Source Type: research

Safety and efficacy of non ‐vitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: a study‐level meta‐analysis of phase III randomized trials
ConclusionsResults of this meta‐analysis support the safety and efficacy of NOACs compared with warfarin in diabetic patients with non‐valvular AF.
Source: Diabetes/Metabolism Research and Reviews - October 31, 2016 Category: Endocrinology Authors: Giuseppe Patti, Giuseppe Di Gioia, Ilaria Cavallari, Antonio Nenna Tags: REVIEW ARTICLE Source Type: research